Compass Therapeutics (NASDAQ:CMPX) Stock Price Target Lowered at Wedbush

Key Points

• Wedbush lowered its price target on Compass Therapeutics from $1.00 to $0.90 and maintained a neutral rating, implying about 3.1% upside from the then-current share price.
• Analyst opinions are mixed, but MarketBeat’s consensus was “Moderate Buy” with a $9.99 average price target; individual ratings ranged from strong buy to sell.
• Shares traded at $0.87 after rising 4.3% on Tuesday. The company also reported a quarterly loss of $0.15 per share, missing the $0.13 loss analysts expected.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) had its price target lowered by research analysts at Wedbush from $1.00 to $0.90 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a "neutral" rating on the stock. Wedbush's target price indicates a potential upside of 3.09% from the stock's current price.

A number of other research analysts have also recently weighed in on CMPX. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Compass Therapeutics in a research report on Thursday, October 15th. Guggenheim reduced their target price on shares of Compass Therapeutics to $4.00 and set a "buy" rating for the company in a report on Wednesday, September 23rd. Piper Sandler raised their target price on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Wall Street Zen downgraded shares of Compass Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 8th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Compass Therapeutics in a report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $9.99.

Compass Therapeutics Trading Up 4.3%

NASDAQ CMPX traded up $0.04 on Tuesday, hitting $0.87. 531,937 shares of the company traded hands, compared to its average volume of 4,512,036. The company has a market capitalization of $157.22 million, a price-to-earnings ratio of -2.17 and a beta of 1.06. The business's 50 day moving average price is $1.26 and its 200-day moving average price is $3.08. Compass Therapeutics has a 52-week low of $0.67 and a 52-week high of $6.88.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). As a group, sell-side analysts predict that Compass Therapeutics will post -0.47 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Palo Alto Investors LP purchased a new position in shares of Compass Therapeutics during the second quarter valued at about $12,771,670. BlackRock Inc. bought a new stake in shares of Compass Therapeutics in the second quarter worth about $24,707,000. Squarepoint Ops LLC increased its holdings in shares of Compass Therapeutics by 1,906.9% in the second quarter. Squarepoint Ops LLC now owns 1,007,507 shares of the company's stock worth $2,206,000 after purchasing an additional 957,305 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Compass Therapeutics by 224.9% in the first quarter. Bank of America Corp DE now owns 865,613 shares of the company's stock worth $4,579,000 after buying an additional 599,179 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Compass Therapeutics in the second quarter worth about $1,147,000. Institutional investors own 68.43% of the company's stock.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company's research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.